Acumen Pharmaceuticals Inc. (ABOS), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, is scheduled to report its third-quarter 2025 financial results on Wednesday, November 12. Analysts are projecting a net loss of $0.68 per share for the quarter, reflecting continued investment in its lead program and pipeline development.
Phase 2 Study: ALTITUDE-AD
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com